Real-world results and experiences with mavacamten in obstructive hypertrophic cardiomyopathy
Observes how adults with obstructive hypertrophic cardiomyopathy fare on mavacamten in everyday care.
Plain-language title generated from the registry record
Registry title: Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Key facts
- Where
- Bollington, United KingdomSee the site
Where in United Kingdom
- Adelphi Real WorldBollington, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07557498
- Record updated
- 29 April 2026
- Original description
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practiceRead full original descriptionShow less
Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
Inclusion: Phase I: retrospective chart review; For inclusion in the study, participants must meet ALL of the following criteria:; Are an adult aged 18 or over at baseline; Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM); Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024; Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted); Are not enrolled in any interventional clinical trial at study baseline; Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey.
Exclusion: None with the proviso that all inclusion criteria are met.